Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
暂无分享,去创建一个
R. Rappuoli | M. Levine | G. Losonsky | M. Pizza | G. Losonsky | J. Galen | E. Barry | S. Chatfield | O. Gómez-Duarte | Steven N. Chatfield | Myron M. Levine | Eileen M. Barry | Oscar GOMEZ-DUARTE
[1] M. Levine,et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. , 1997, Vaccine.
[2] W. Blackwelder,et al. A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.
[3] J. Eldridge,et al. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1995, Infection and immunity.
[4] R. Rappuoli,et al. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. , 1995, Vaccine.
[5] G. Lewis,et al. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. , 1995, Vaccine.
[6] G. Dougan,et al. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. , 1994, Journal of immunology.
[7] C. Locht,et al. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein , 1994, Infection and immunity.
[8] D. Cohen,et al. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models , 1993, Infection and immunity.
[9] R. Rappuoli,et al. Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin , 1992, Infection and immunity.
[10] Ian G. Charles,et al. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis , 1992, Infection and immunity.
[11] K. Timmis,et al. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit , 1992, Infection and immunity.
[12] I. Charles,et al. Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus Vaccine , 1992, Bio/Technology.
[13] M. Levine,et al. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. , 1992, Vaccine.
[14] K. Timmis,et al. Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis , 1991, Infection and immunity.
[15] G. Dougan,et al. Construction of genetically defined double aro mutants of Salmonella typhi. , 1991, Vaccine.
[16] H. Sato,et al. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies , 1991, Infection and immunity.
[17] I. Charles,et al. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. , 1991, Nucleic acids research.
[18] M. Kimura. Japanese clinical experiences with acellular pertussis vaccines. , 1991, Developments in biological standardization.
[19] H. Sato,et al. Protective activities in mice of monoclonal antibodies against pertussis toxin , 1990, Infection and immunity.
[20] C. Locht,et al. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin , 1990, Infection and immunity.
[21] N. Fairweather,et al. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier , 1990, Infection and immunity.
[22] L. Nencioni,et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough , 1990, Infection and immunity.
[23] S. Stibitz,et al. Cloning and expression of functional fragment C of tetanus toxin , 1990, Infection and immunity.
[24] L. Nencioni,et al. Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.
[25] K. J. Kim,et al. Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. , 1989, Hybridoma.
[26] S. Busby,et al. Mutational analysis of the nucleotide sequence at the FNR-dependent nirB promoter in Escherichia coli. , 1989, Nucleic acids research.
[27] R. Curtiss,et al. Selective delivery of antigens by recombinant bacteria. , 1989, Current topics in microbiology and immunology.
[28] P. Jayaraman,et al. Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia coli and its regulation by oxygen, the Fnr protein and nitrite. , 1987, Journal of molecular biology.
[29] G. Dougan,et al. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system , 1987, Parasite immunology.
[30] A. Ferrante,et al. Staphylococcus aureus-stimulated human mononuclear leucocyte-conditioned medium augments the basal and stimuli-induced neutrophil respiratory burst and degranulation. , 1987, Immunology.
[31] C. Locht,et al. Pertussis toxin gene: nucleotide sequence and genetic organization. , 1986, Science.
[32] J. Chiba,et al. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections , 1984, Infection and immunity.
[33] M. Pittman. The concept of pertussis as a toxin‐mediated disease , 1984, Pediatric infectious disease.
[34] T. Katada,et al. The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. , 1983, Archives of biochemistry and biophysics.
[35] M. Ui,et al. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. , 1983, The Journal of biological chemistry.
[36] E. Hewlett,et al. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin , 1983, Infection and immunity.
[37] T. Katada,et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. , 1982, Biochemistry.
[38] B. Stocker,et al. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines , 1981, Nature.